Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai’s Dacogen Final Results On Overall Survival Get Preliminary Test At U.S. FDA Advisory Committee

This article was originally published in PharmAsia News

Executive Summary

Preliminary evidence from the pivotal trial of decitabine for acute myelogenous leukemia showed the increase in overall survival wasn’t statistically significant, but final results show a benefit of more than 50% compared with the control arm.

You may also be interested in...

Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges

Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.

Halaven Survival Data Was Gold-Standard Lining In Forced Shift From Accelerated To Full Approval

Eisai’s development plan for Halaven was derailed by FDA’s approval of Ixempra in the same metastatic breast cancer indication, precluding the planned accelerated approval filing and redirecting the sponsor to a full approval track, but it also meant eribulin received the first approval in its highly refractory patient population ever to be based on overall survival data.

Janssen’s Sirturo Needs Minor Tweaks To Confirmatory Trial, FDA Panel Says

Gathering more data to assuage concerns about possibly lower efficacy in black patients will be key to converting the accelerated approval to full approval for the tuberculosis drug, FDA’s Anti-Infective Drugs Advisory Committee concludes.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts